Schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorder NOS or any other psychotic disorder patients demanding long term antipsychotic treatment MedDRA version: 9.1 Level: LLT Classification code 10037253 Term: Psychotic disorder NOS MedDRA version: 9.1 Level: LLT Classification code 10061920 Term: Psychotic disorder MedDRA version: 9.1 Level: HLGT Classification code 10039628 Term: Schizophrenia and other psychotic disorders MedDRA version: 9.1 Level: HLT Classifica
Conditions
Interventions
Pharmaceutical Form:
Sponsors
Janssen-Cilag AB
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Written informed consent obtained from patient; 2. Male or female adult patient >= 18 years old; 3. Patient diagnosed with schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorder NOS or any other psychotic disorder demanding long term antipsychotic treatment; 4. The patient’s psychotic symptoms has, according to clinical judgment, been stable during the past three months without a need for major interventions due to clinical deterioration (like hospitalization and/or major changes in medication); 5. Patients current main antipsychotic therapy is: a. Atypical oral antipsychotic; or b. Atypical long acting injectable (LAI) antipsychotic; or c. Conventional LAI antipsychotic. 6. Patient should have been treated with their current main antipsychotic therapy for a minimum of 6 months and a maximum of 24 months. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Patient experiencing an acute relapse/exacerbation of schizophrenia symptoms; 2. Patient registered on involuntary/compulsory therapy (LPT and forensic patients); 3. Patient currently participating in a randomized controlled trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary objective of the study is to compare overall patient treatment satisfaction with current medication in patients with schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorder NOS (not otherwise specified) or any other psychotic disorder. Three treatment groups will be included: 1) Atypical oral antipsychotics; 2) Conventional LAI antipsychotics; 3) Atypical LAI antipsychotic (Risperdal Consta®).;Secondary Objective: Patient perception of efficacy and effectiveness, functioning, adverse events and adherence with their current treatment will be investigated. Patient attitudes towards, and preferences for, administration formulation, as well as their perception of information received regarding different treatment options will also be studied. For patients on atypical oral therapy without previous experience of LAI therapy specific questions will address willingness to consider antipsychotic LAI therapy as a treatment option. Physicians’ clinical global impression of severity, assessment of adherence and patient medication satisfaction, and attitudes towards different types of antipsychotic treatment will be studied. Physicians’ reasons for prescribing, and switching between, the different treatment options will be investigated.;Primary end point(s): The primary objective of the study is to compare overall patient treatment satisfaction with current medication in patients with schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorder NOS (not otherwise specified) or any other psychotic disorder. Three treatment groups will be included: 1) Atypical oral antipsychotics; 2) Conventional LAI antipsychotics; 3) Atypical LAI antipsychotic (Risperdal Consta®). | — |
Countries
Finland
Outcome results
None listed